Table 1.
Baseline Characteristics in Study Group
| Baseline characteristic | Total (n = 150) | Peripheral neuropathy |
|
| Present (n = 17; 11%) | Absent, (n = 133; 89%) | ||
| Female sex, no. (%) | 98 (65.3) | 16 (94.1) | 82 (61.7) |
| Age, median (range; IQR), years | 35 (19–61; 31–41) | 34 (32–42) | 35 (31–41) |
| Baseline CD4 count, median (IQR), cells/μL | 142 (64–208) | 170 (116–242) | 136 (55–204) |
| Baseline weight, median (IQR), kg | 57 (49.1–63.7) | 59.4 (53.7–69.1) | 57.0 (48.3–63.6) |
| Baseline height, median (IQR), cm | 164 (158–170) | 163.5 (158.5–167.5) | 164 (157.3–170) |
| Baseline BMI, median (IQR), kg/m2 | 20.7 (18.3–24.4) | 22.4 (20.3–25.3) | 20.4 (18.1–24) |
| WHO clinical stage of HIV infection, no. (%) | |||
| Stage 1 | 21 (14.0) | 3 (17.6) | 18 (13.5) |
| Stage 2 | 42 (28.0) | 4 (23.5) | 38 (28.6) |
| Stage 3 | 83 (55.3) | 10 (58.8) | 73 (54.9) |
| Stage 4 | 4 (2.6) | 0 (0) | 4 (3.0) |
| Initial NRTI backbone, no. (%) | |||
| Zidovudine | 53 (35) | 4 (23.5) | 49 (36.8) |
| Weight-based stavudine | 94 (63) | 13 (76.5) | 81 (60.9) |
| Tenofovir or abacavir | 3 (2) | 0 (0) | 3 (2.3) |
| Duration of observation during ART, median (IQR), days | 366 (351–399) | 293 (160–369) | 370 (355–402) |
| TB treatmenta completed before study entry, no. (%) | 6 (4.0) | 1 (6.8) | 5 (3.8) |
| TB treatmenta received during study period, no. (%) | 26 (17.3) | 3 (18.6) | 23 (17.3) |
| History of diabetes, no. (%) | 0 (0) | … | … |
| Baseline hemoglobin, median (IQR), g/dL | 9.8 (8.5–11.5) | 9.1 (8.4–9.8) | 10.0 (8.5–11.6) |
NOTE. ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; NRTI, nucleoside reverse-transcriptase inhibitor; TB, tuberculosis; WHO, World Health Organization.
a
All TB treatment regimens included both isoniazid and ethambutol.